Novo’s Nash play takes shape
Novo Nordisk Snags FDA Approval for Oral Type 2 Diabetes Drug
Lilly's Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?
Novo Nordisk's Ozempic Continues to Show Superiority in Diabetes Control
With Obesity on the Continued Rise in the U.S., More Anti-Obesity Drugs Are Heading for the Market
Novo hopes slimmed-down bet can still win in obesity
Novo Nordisk's semaglutide is headed toward a Lilly showdown. Will Novo speed it up?
Novo’s next big diabetes bet heads to regulators
Lilly's under-pressure Trulicity scores with first-of-its-kind cardio outcomes win
Novo Nordisk boosts its GLP-1 score with yet more evidence for crucial semaglutide pill